What is the 13F Pro Quality Score for PAVM?

13F Pro ranks PAVmed Inc. (PAVM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PAVM's current score at https://13fpro.ai/research/PAVM (free sign-up required for the full ranking).

Which hedge funds own the most PAVM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PAVM include Two Seas Capital, FIRST MANHATTAN CO., GEODE CAPITAL MANAGEMENT,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PAVM as soon as new 13F filings post.

Where does 13F Pro source PAVM data?

All PAVmed Inc. fundamentals and ownership data come directly from SEC EDGAR. PAVmed Inc. files with the SEC under CIK 1624326. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PAVM in?

PAVmed Inc. (PAVM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PAVM research updated on 13F Pro?

PAVM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PAVmed Inc.(PAVM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1624326 PAVM stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PAVM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PAVmed Inc. (PAVM), a Healthcare sector company. PAVM is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), PAVmed Inc. reports quarterly revenue of $22.0K, net income of $-60.0K, free cash flow of $-2.6M. Top institutional holders of PAVM by reported 13-F value include Two Seas Capital, FIRST MANHATTAN CO., GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. PAVM trades on the Nasdaq exchange and files with the SEC under CIK 1624326. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PAVM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PAVmed Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$22.0K

Net Income

Q1 2026

$-60.0K

Free Cash Flow

Q1 2026

$-2.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+695.8% YoY

$3.0MFY 2024

FY16 —FY17 —FY22 $377.0KFY24 $3.0M

Net Income

+144.7% YoY

$39.8MFY 2024

FY16 $-5.7MFY17 $-9.5MFY22 $-89.0MFY24 $39.8M

Operating Income

+51.2% YoY

$-44.5MFY 2024

FY16 $-5.7MFY17 $-8.0MFY22 $-91.1MFY24 $-44.5M

EPS (Diluted)

+1686.3% YoY

$9.93FY 2024

FY16 —FY17 —FY22 $-0.63FY24 $9.93

Total Assets

-43.2% YoY

$30.7MFY 2024

FY16 $870.4KFY17 $1.6MFY22 $54.0MFY24 $30.7M

Op. Cash Flow

+52.7% YoY

$-33.6MFY 2024

FY16 —FY17 $-6.6MFY22 $-71.0MFY24 $-33.6M

Metric	FY 2024	FY 2022	FY 2017	FY 2016	FY 2015	FY 2014
Revenue	$3.0M +695.8%	$377.0K	—	—	—	—
Net Income	$39.8M +144.7%	$-89.0M -834.8%	$-9.5M -68.5%	$-5.7M -218.1%	$-1.8M	—
Operating Income	$-44.5M +51.2%	$-91.1M -1033.8%	$-8.0M -42.2%	$-5.7M	—	—
EPS (Diluted)	$9.93 +1686.3%	$-0.63	—	—	—	—
Total Assets	$30.7M -43.2%	$54.0M +3192.1%	$1.6M +88.4%	$870.4K -28.3%	$1.2M	—
Operating Cash Flow	$-33.6M +52.7%	$-71.0M -974.2%	$-6.6M	—	—	—

AI Insight: PAVM Financial Trends

PAVmed remains pre-revenue with persistent operating losses and negative cash flow; equity swung from deeply negative to modest positive but deteriorated since Q1 2025.

• Revenue flat at $0M across last eight quarters; company has generated no meaningful commercial traction.

• Operating income losses narrowed from $-14M in Q2 2024 to $-5M to $-8M range in 2025–Q1 2026.

• Equity recovered from $-74M (Q2 2024) to $40M (Q1 2026), reversing prior deep deficit structure.

⚠ Operating cash flow remains persistently negative ($-1M to $-12M per quarter); burn ongoing despite no revenue.

⚠ Equity peaked at $45M in Q1 2025 but has declined $5M since; operating losses suggest further erosion ahead.

AI Insight: PAVM Ratio Trends

PAVmed remains deeply unprofitable with ROIC deteriorating to -81.3% in Q1 2026, though near-term losses are narrowing sharply.

• ROE collapsed from +168.6% in Q1 2025 to -0.6% in Q1 2026; ROA similarly recovered from -56.6% in Q3 2025 to -0.5% in latest quarter.

• ROIC worsened to -81.3% in Q1 2026 from -80.1% in Q4 2025, extending 18-month trend of deeply negative capital returns.

• TTM metrics show sustained unprofitability: ROE -47.1%, ROA -41.0%, ROIC -61.7% as of March 2026.

⚠ Quarterly profitability swings mask persistent inability to generate positive returns; Q1 2026 improvement may reflect seasonal trough, not operational inflection.

⚠ ROIC gap between Q1 2026 (-81.3%) and TTM (-61.7%) signals recent quarters significantly worse than 12-month average.

Get alerted when PAVM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PAVmed Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PAVM

Two Seas Capital LP
$4.7M461,539 sh
FIRST MANHATTAN CO. LLC.
$241.6K23,805 sh
GEODE CAPITAL MANAGEMENT, LLC
$119.5K11,777 sh
Byrne Asset Management LLC
$65.2K6,420 sh
VANGUARD CAPITAL MANAGEMENT LLC
$60.1K5,917 sh
VANGUARD FIDUCIARY TRUST CO
$55.1K5,429 sh
BlackRock, Inc.
$24.5K2,416 sh
Tower Research Capital LLC (TRC)
$6.3K622 sh
MORGAN STANLEY
$1.7K165 sh
CWM, LLC
$1.6K157 sh

Fund	Value	Shares
Two Seas Capital LP	$4.7M	461,539
FIRST MANHATTAN CO. LLC.	$241.6K	23,805
GEODE CAPITAL MANAGEMENT, LLC	$119.5K	11,777
Byrne Asset Management LLC	$65.2K	6,420
VANGUARD CAPITAL MANAGEMENT LLC	$60.1K	5,917
VANGUARD FIDUCIARY TRUST CO	$55.1K	5,429
BlackRock, Inc.	$24.5K	2,416
Tower Research Capital LLC (TRC)	$6.3K	622
MORGAN STANLEY	$1.7K	165
CWM, LLC	$1.6K	157

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PAVM on your watchlist

Track score changes the day PAVmed Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PAVM a good stock to buy?

13F Pro's AI-powered analysis of PAVmed Inc. (PAVM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PAVM are available on the PAVM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PAVM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PAVM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PAVmed Inc.'s investment landscape.